Awakn Partners With University Of Nottingham For Preclinical Testing Of Psychoactive Therapy
Awakn Partners With University Of Nottingham For Preclinical Testing Of Psychoactive Therapy
Awakn Life Sciences Corp. (OTC:AWKNF), a clinical-stage biotechnology company, has announced a new partnership with the University of Nottingham to conduct in vivo testing of its aminoindane new chemical entity as part of its preclinical program. This research will explore the therapeutic potential of Awakn's aminoindane, or psychoactive, series in enhancing social cognition and pro-social behaviors, particularly for trauma-related mental health disorders such as PTSD.
Awakn生命科學公司(OTC:AWKNF)，一家臨床階段生物技術公司，已宣佈與諾丁漢大學建立新合作伙伴關係，進行體內測試其氨基茚新化合物，作爲其臨床前項目的一部分。此研究將探索Awakn的氨基茚，或致幻，系列在增強社交認知和親社會行爲方面的治療潛力，特別是針對創傷相關的精神健康障礙，如創傷後應激障礙。
The study, led by Dr. Madeleine King, an expert in behavioral neuroscience, will utilize rodent models to evaluate the compound's efficacy through the Social Transmission of Food Preferences test. Results from the trial are expected by the end of 2024. This partnership follows Awakn's recent collaboration with Eurofins Discovery for in vitro pharmacology testing of the same aminoindane series, marking significant progress in Awakn's research and development pipeline.
由行爲神經科學專家Madeleine King博士領導的研究將利用齧齒動物模型來評估該化合物通過社會傳播食物偏好測試的療效。預計該試驗結果將在2024年底前出爐。這一合作是Awakn最近與Eurofins Discovery合作進行相同氨基茚系列體外藥理學測試的延伸，標誌着Awakn在研發管線方面取得了重大進展。
Anthony Tennyson, CEO of Awakn Life Sciences, emphasized the significance of the partnership: "We believe this novel aminoindane has the potential to revolutionize mental health treatment, offering a safer alternative for trauma-related disorders such as PTSD."
Awakn生命科學公司首席執行官Anthony Tennyson強調了這一合作的重要性：「我們相信這種新型氨基茚有潛力革新精神健康治療，爲創傷相關障礙如創傷後應激障礙提供更安全的替代方案。」
Cover image made with AI
封面圖片由人工智能製作
譯文內容由第三人軟體翻譯。
